balversa 3 mg
j-c health care ltd - erdafitinib - film coated tablets - erdafitinib 3 mg - erdafitinib - balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc), that has:- susceptible fgfr3 or fgfr2 genetiic alterations, and- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
balversa 4 mg
j-c health care ltd - erdafitinib - film coated tablets - erdafitinib 4 mg - erdafitinib - balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc), that has:- susceptible fgfr3 or fgfr2 genetiic alterations, and- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
balversa 5 mg
j-c health care ltd - erdafitinib - film coated tablets - erdafitinib 5 mg - erdafitinib - balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc), that has:- susceptible fgfr3 or fgfr2 genetiic alterations, and- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
balversa 4 mg
مستودع أدوية أداتكو - adatco drug store - erdafitinib 4 mg - 4 mg
balversa 5 mg
مستودع أدوية أداتكو - adatco drug store - erdafitinib 5 mg - 5 mg
balversa 4 mg
مستودع أدوية أداتكو - adatco drug store - erdafitinib 4 mg - 4 mg
balversa 4 mg
مستودع أدوية أداتكو - adatco drug store - erdafitinib 4 mg - 4 mg